140,000-Person UK Trial Data Validates Single Blood Test for Early Detection of 50 Cancers

The medical community now has its first definitive, population-scale look at the efficacy of multi-cancer early detection screening. Detailed results from the landmark NHS-Galleri trial, which tracked 142,250 asymptomatic participants in England over three years, were released at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. As the largest randomized controlled trial of a blood-based cancer screening tool ever conducted, the data provides a rigorous evidence pack detailing exactly what the technology can and cannot do.[1][2]

The Galleri test, developed by healthcare company GRAIL, operates on a mechanism of analyzing cell-free DNA (cfDNA) in the bloodstream. Tumors shed fragments of DNA as they grow, and the test uses artificial intelligence to identify specific methylation patterns associated with more than 50 types of cancer. Crucially, this includes highly lethal malignancies that currently lack any routine screening protocols, such as pancreatic, liver, and ovarian cancers.[1]

The trial's primary statistical endpoint was ambitious: to prove that annual testing could significantly reduce the combined incidence of Stage III and Stage IV diagnoses across 12 prespecified cancers. According to the data presented at ASCO, the trial failed to meet this combined primary endpoint. The reduction in Stage III and IV cancers together did not reach the threshold for statistical significance when compared to the control group receiving standard care.[1]

Critics and some oncology delegates were quick to highlight the shortfall, with some declaring the trial a failure because it did not definitively prove a broad reduction in late-stage disease. For skeptics of widespread genomic screening, the missed primary endpoint serves as a warning against rolling out expensive new diagnostics before their population-level benefits are unequivocally proven.

However, a deeper analysis of the secondary endpoints reveals a highly nuanced success story. When isolating Stage IV (metastatic) cancers—the deadliest and most difficult to treat—the test demonstrated a 14% reduction overall. This benefit compounded over time, improving to a 22% reduction in the second annual screening round and a 26% reduction by the third round.[1][3]

The data also confirmed significant gains in early detection. The trial recorded a 16% increase in the diagnosis of Stage I and II cancers among participants who received the Galleri test compared to those who only received standard-of-care screenings like mammograms and colonoscopies. By catching these tumors earlier in their progression, the blood test increased the overall cancer detection rate four-fold.[1]

One of the most critical public health metrics validated by the trial was a 25% reduction in cancers diagnosed through emergency hospital presentations. Patients who discover their cancer during an emergency room visit historically face the poorest survival outcomes, making this reduction a tangible victory for proactive healthcare intervention.[1]

For any population-level screening program, the risk of false positives—which can lead to unnecessary anxiety, invasive biopsies, and wasted medical resources—is a paramount concern. The NHS-Galleri data confirmed that the test is exceptionally precise, validating a specificity of 99.55%. This translates to a false-positive rate of just 0.45%, meaning fewer than 1 in 200 healthy individuals received a false alarm.[1]

The trial also established a Positive Predictive Value (PPV) of 52.0%. In clinical terms, this means that if a participant received a positive "cancer signal detected" result, there was a slightly better than 50% chance that subsequent diagnostic imaging and biopsies would confirm the presence of a malignancy. In the first screening round specifically, the PPV was even higher at 58.0%.[1]

When the test did detect a cancer signal, it proved highly adept at directing oncologists where to look. The test correctly predicted the cancer's tissue of origin—such as the lungs, pancreas, or lymphatic system—with 92.5% accuracy. This capability is vital for streamlining the diagnostic workup, ensuring patients are sent to the correct specialist for immediate imaging rather than undergoing a blind search.[1]

Despite these successes, the evidence pack highlights ongoing biological limitations regarding sensitivity. The test's overall sensitivity was 30.7% across all cancers, rising to 54.7% for the prespecified group of 12 highly lethal cancers. The data confirms that the test remains much better at detecting aggressive, later-stage tumors that shed large amounts of DNA than it is at finding very early, slow-growing cellular anomalies.[1]

This limitation is particularly relevant for specific diseases like ovarian cancer, which is notoriously difficult to catch early. Advocacy groups and researchers analyzing the data noted that while the test successfully detects ovarian malignancies, it still struggles to catch them at Stage I. This underscores the reality that cfDNA screening is not a magic bullet for all early-stage detection.

The comprehensive dataset now moves to regulatory bodies for evaluation. The UK National Screening Committee will review the findings to determine if the clinical utility and health economics justify a nationwide rollout across the National Health Service. Simultaneously, the U.S. Food and Drug Administration continues to review the test's premarket approval application, which will also incorporate data from the ongoing American REACH trial.[1][2]

Ultimately, the 140,000-person trial proves that while multi-cancer early detection is not a flawless "holy grail" that eliminates all late-stage disease, it is a highly specific, functional tool. By successfully shifting a meaningful percentage of diagnoses away from the deadliest metastatic stages and drastically reducing emergency presentations, the data validates cfDNA screening as a powerful new layer in modern oncology.[3]